Understanding racial differences in colorectal cancer aids in individualized medicine

Future Oncology

Volumn 3, Issue 3, 2007, Pages 235-241

  Manne, Upender ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN BAX; PROTEIN P53;

ADJUVANT THERAPY; AFRICAN AMERICAN; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; EDITORIAL; ETHNIC DIFFERENCE; HUMAN; HYPERTENSION; KIDNEY FAILURE; OSTEOARTHRITIS; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RECTUM CARCINOMA; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; UNITED STATES;

EID: 34347397180     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.235     Document Type: Editorial

References (62)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
2. Weaver P, Harrison B, Eskander G et al.: Colon cancer in African-Americans: a disease with a worsening prognosis. J. Natl Med. Assoc. 83(2), 133-136 (1991).
3. Alexander D, Chada C, Funkhouser E, Meleth S, Grizzle WE, Manne U: Postsurgical disparity in survival between African-Americans and Caucasians with colonic adenocarcinoma. Cancer 101 (1), 66-76 (2004).
4. Alexander D, Jhala N, Chatla C et al.: High-grade tumor differentiation is an indicator of poor prognosis in African-Americans with colonic adenocarcinomas. Cancer 103(10), 2163-2170 (2005).
5. Doubeni CA, Field TS, Buist DS et al.: Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer 109(3), 612-620 (2007).
6. Krieger N: Does racism harm health? Did child abuse exist before 1962? On explicit questions, critical science, and current controversies: an ecosocial perspective. Am. J. Public Health 93(2), 194-199 (2003).
7. Polite BN, Dignam JJ, Olopade OI: Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J. Clin. Oncol. 24(14), 2179-2187 (2006).
8. Irby K, Anderson WF, Henson DE, Devesa SS: Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002). Cancer Epidemiol. Biomarkers Prev. 15(4), 792-797 (2006).
9. Larson W: Development of the gastrointestinal tract. In: Human embryology. Churchill Livingstone, Inc, NY, USA 205-234 (1993).
10. Grizzle WE, Shibata D, Manne U: Molecular and histopathologic changes in the development of colorectal neoplasia. In: Molecular Pathology of Early Cancer. Gazdar (Eds). IOS Press, Amsterdam, The Netherlands 197-220 (1999).
11. Kern SE, Fearon ER, Tersmette KW et al.: Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 261(21), 3099-3103 (1989) (published erraturn appears in JAMA 262(14), 1952 [1989]).
12. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P: P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J Cancer 63(2), 317-319 (1991).
13. Delattre O, Olschwang S, Law DJ et al.: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2(8659), 353-356(1989).
14. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260(5109), 816-819 (1993).
15. Coates RJ, Greenberg RS, Liu MT et al.: Anatomic site distribution of colon cancer by race and other colon cancer risk factors. Dis. Colon Rectum 38(1), 42-50 (1995).
16. Devesa SS, Chow WH: Variation in colorectal cancer incidence in the united states by subsite of origin. Cancer 71(12), 3819-3826(1993).
17. Demers RY, Severson RY, Schottenfeld D, Lazar L: Incidence of colorectal adenocarcinoma by anatomic subsite. An epidemiologic study of time trends and racial differences in the Detroit, Michigan area. Cancer 79(3), 441-447 (1997).
18. Johnson H Jr, Carstens R: Anatomical distribution of colonic carcinomas. Interracial differences in a community hospital population. Cancer 58 (4), 997-1000 (1986).
19. Dignam JJ, Colangelo L, Tian W et al.: Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the national surgical adjuvant breast and bowel project. J. Natl Cancer Inst. 91(22), 1933-1940 (1999).
20. Dominitz JA, Samsa GP, Landsman P, Provenzale D: Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 82(12), 2312-2320(1998).
21. Rabeneck L, Davila JA, El-Serag HB: Is there a true "shift" to the right colon in the incidence of colorectal cancer? Am. J. Gastroenterol. 98(6), 1400-1409 (2003).
22. Nelson RL, Dollear T, Freels S, Persky V: The relation of age, race, and gender to the subsite location of colorectal carcinoma (see comments]. Cancer 80(2), 193-197 (1997).
23. Agrawal S, Bhupinderjit A, Bhutani MS et al.: Colorectal cancer in African-Americans. Am. J. Gastroenterol. 100(3), 515-523 (2005).
24. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256(5058), 827-830 (1992).
25. Kern SE, Fearon ER, Tersmette KW et al.: Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 261(21), 3099-3103 (1989).
26. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M: Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 6(3), 273-281 (1994).
27. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur. J. Cancer 32A(11), 1963-1967(1996).
28. Manne U, Weiss HL, Myers RB et al.: Nuclear accumulation of p53 in colorectal. adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer 83, 2456-2467 (1998).
29. Mayberry RM, Coates RJ, Hill HA et al.: Determinants of black/ white diifferences in colon cancer survival. J. Natl. Cancer Inst. 87(22), 1686-1693 (1995).
30. Nagel S, Chung EB, DeWitty RL Jr, Leffall LD Jr: Colorectal cancer in young black patients. JAMA 80(1), 37-40 (1988).
31. Chen VW, Fenoglio-Preiser CM, Wu XC et al.: Aggressiveness of colon carcinoma in blacks and whites. National cancer institute black/ white cancer survival study group. Cancer Epidemiol. Biomarkers Prev. 6(12), 1087-1093 (1997).
32. Katkoori V, Goli R, Jia X et al.: Prognostic value of molecular alterations in high grade colorectal adenocarcinomas varies in African-Americans and Caucasians. In: American Association for Cancer Research. (Abstract 141), Los Angeles, USA 2007.
33. Carethers JM, Smith EJ, Behling CA et al.: Use of 5-fluorouracil and survival in patients with microsatellite-unstable coloreccal cancer. Gastroenterology 126(2), 394-401 (2004).
34. Ribic CM, Sargent DJ, Moore MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
35. Ishioka C, Suzuki T, Kanamaru R: Mutations of p53 gene in human colorectal tumor in Japan: molecular epidemiological aspects. Tohoku J. Exp. Med. 167(3),243-245 (1992).
36. Ventura A, Kirsch DG, McLaughlin ME et al.: Restoration of p53 function leads to tumour regression in vivo. Nature 445(7128), 661-665 (2007).
37. Xue W, Zender L, Miething C et al.: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128), 656-660 (2007).
38. Zhang L, Yu D, Hu M et al.:Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60(13), 3655-3661 (2000).
39. Bykov VJ, Issaeva N, Shilov, A et al.: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8(3),282-288 (2002).
40. Haupt S, Haupt Y: Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol. 14(4), 244-252 (2004).
41. Vassilev LT, Vu BT, Graves B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of mdm2. Science 303(5659), 844-848 (2004).
42. Ball JK, Elixhauser A: Treatment differences between blacks and whites with colorectal cancer. Med. Care 34(9), 970-984 (1996).
43. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J. Natl. Cancer Inst. 94(5), 334-357 (2002).
44. Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR: Racial comparison of outcomes of male department of veterans affairs patients with lung and colon cancer. Arch. Intern. Med. 153(14), 1681-1688(1993).
45. Rabeneck L, Souchek J, El-Serag HB: Survival of colorectal cancer patients hospitalized in the veterans affairs health care system. Am. J. Gastroenterol. 98(5), 1186-1192 (2003).
46. Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucavorin for metastatic colorectal cancer. Irinotecan study group [see comments]. N. Engl. J. Med. 343(13), 905-914 (2000).
47. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000).
48. de Gramont A, Vignoud J, Tournigand C et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 33(2), 214-219 (1997).
49. Andre T, Sargent D, Tabernero J et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 13(6), 887-898 (2006).
50. Andre T, Tournigand C, Achille E et al.: Adjuvant treatment of colon cancer mosaic srudys main results. Bull. Cancer 93(Suppl. 1), S5-S9 (2006).
51. Sun W, Haller DG: Adjuvant therapy for colon cancer. Curr. Oncol. Rep. 7(3), 181-185 (2005).
52. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217), 1745-1750 (2000).
53. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione s-transferase p1, t1, and m1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94(12), 936-942 (2002).
54. Midgley R, Kerr DJ: Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat. Clin. Pract. Oncol. 2(7), 364-369 (2005).
55. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF: Age, sex, and racial differences in the use of standard adjuvant therapy fbr colorectal cancer. J. Clin. Oncol. 20(5), 1192-1202 (2002).
56. Tejeda HA, Green SB, Trimble EL et al.: Representation of African-Americans, hispanics, and whites in national cancer institute cancer treatment trials. J. Natl. Cancer Inst. 88(12), 812-816 (1996).
57. McCollum AD, Catalano PJ, Haller DG et al.: Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 94(15), 1160-1167 (2002).
58. Dignam JJ, Ye Y, Colangelo L et al.: Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. J. Clin. Oncol. 21(3), 413-420 (2003).
59. Mor V, Guadagnoli E, Masterson-Allen S et al.: Lung, breast, and colorectal cancer: the relationship between extent of disease and age at diagnosis. J. Am. Geriatr. Soc. 36(10), 873-876 (1988).
60. Meyerhardt JA, Catalano PJ, Haller DG et al.: Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 21(3),433-440 (2003).
61. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Impact of comorbidity on lung cancer survival. Int. J. Cancer 103(6), 792-802 (2003).
62. Alexander D, Water J, Hughes T, Funkhouser E, Grizzle W, Manne U: African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomarkers (2007) (In Press).